BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, November 12th @ 8:30am ETDomestic:1-844- ...

Core Viewpoint - CorMedix Inc. plans to offer and sell $85.0 million of its common stock in an underwritten public offering, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] - RBC Capital Markets is acting as the sole bookrunner for the offering [2] - The net proceeds will be used for general corporate purposes, including working capital and research expenses [2] Group 2: Regulatory Information - The securities are being offered under a shelf registration statement filed with the SEC on May 6, 2024, and declared effective on May 22, 2024 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on their website [4] Group 3: Company Overview - CorMedix is focused on developing therapeutic products for life-threatening conditions, with its lead product DefenCath® approved by the FDA on November 15, 2023 [6] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [6] - The company plans to commence clinical studies in Total Parenteral Nutrition and Pediatric populations in 2025 [6]

Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [3] - The company is commercializing its lead product DefenCath® (taurolidine and heparin), which was approved by the FDA on November 15, 2023 [3] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [3] Upcoming Events - CorMedix will participate in the Jefferies Global Healthcare Conference in New York from June 3 to June 5, 2025 [1] - The presentation at the conference is scheduled for June 5, 2025, at 3:45 p.m. EDT [2] Future Developments - The company is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 [3] - CorMedix intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas [3]